Neurodegenerative Disorder Therapeutics Market By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

An increase in the frequency of neurological illnesses

The market for treatments for neurodegenerative disorders is expanding due to an increase in the prevalence of neurodegenerative disorders in the general population. An increase in the elderly population leads to a rise in the prevalence of neurological diseases. According to World Population Prospects, there will be 2.1 billion individuals over 60 in 2050, up from 962 million in 2017, while the number of persons over 80 will treble from 137 million in 2017 to 425 million in 2050. Additionally, research from the Alzheimer's Association indicates that 5.8 million Americans already have Alzheimer's disease, and that figure is predicted to rise to 14 million by 2050. Consequently, an increasing number of neurodegenerative illnesses are among the As the population ages, there is a greater need for treatments for neurological disorders, which propels market expansion.